Nurix Secures $700M Upfront in Global Roche Partnership for Key BTK Degrader
NRIX sits 79% above its 52-week low of $8.195.
Summary
Nurix Therapeutics announced a global collaboration with Roche to co-develop and co-commercialize its BTK degrader, bexobrutideg. Nurix will receive an upfront cash payment of $700 million and is eligible for up to $2.3 billion in development, regulatory, and sales milestones. This deal provides substantial non-dilutive capital, representing nearly half of Nurix's current market capitalization, and leverages Roche's global development and commercialization infrastructure. The partnership significantly de-risks the lead asset and expands its potential across malignant hematology, immunology, and neurology. Nurix will host a conference call tomorrow, June 8, at 8 a.m. ET to discuss the collaboration.
At the time of this announcement, NRIX was trading at $14.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $8.20 to $22.50. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.